Avalere Spotlight: Life Sciences in 2014

The 2014 market will be characterized by challenge and transformation across payers, providers, and patients which will create pressures for the pharmaceutical and medical device industries to:

Evaluating the Usability of CER for Patient and Provider Decision Making

Comparative effectiveness research (CER) has the potential to inform many decisions. While a common threshold for determining whether a CER finding should be disseminated to the public is its methodological quality, a study with high methodological quality is not necessarily one that patients and providers will find usable for their decision making.

The Joint Commission and AMA Identify Five Medical Treatments that May Be Overused

The Joint Commission and the American Medical Association (AMA) Convened Physician Consortium for Performance Improvement® released a report on July 8, which was previously under an embargo, focusing on the overuse of tests, treatments, or procedures that provide zero to negligible benefit and expose patients to risk of harm.

Exchange Operational Models for 2014

In 2014, most states are relying on the federal government for some or all exchange operational functions.

New Research Tracks Impact of CER

New Avalere research found that public and private payers reversed non-coverage policies following a recommendation from a regional CER initiative.

Do You Know Where Your Patients Are Going?

Emerging payment models will demand that hospitals establish tight and narrow networks of high performing post-acute care (PAC) providers.

Sign up to receive more insights about
Please enter your email address to be notified when new insights are published.

Back To Top